This section includes information and resources about Cancer for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results
Boehringer Ingelheim submits first oncology compound, afatinib* for European approval
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*
BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events